C62* (p.Cys62Ter) variant of KRT16 (Keratin, type I cytoskeletal 16)

C62* (p.Cys62Ter) in KRT16 (Keratin, type I cytoskeletal 16) is a protein-truncating change. Clinical records from EBI and UniProt describe it as likely benign. The available variant effect predictions contribute to a CATVariant prioritization score of 0.26 / 1. The record also includes population frequency data and structural context.

C62* (p.Cys62Ter) variant details